GLPG2451 

Small molecule CFTR potentiator

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

GLPG2451  is an experimental substance used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that GLPG2451 can help potentiate G178R-, G551D-, S549N- and R117H-CFTR channels and also corrector-rescued F508del-CFTR.

GLPG2451 on PubChem

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

Structure not available

C16H16F3N3O5S

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 In combination with F508del correction. Better than ivacaftor.
G178R
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.
G551D
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.
R117H
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.
S549N
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.

Does not treat

Mutation Number of sources Average impact factor